Alvotech
NASDAQ:ALVODrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $1.62B
- Beta
- 0.21
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.24
Volume 1.56M
Average 0.65M
ALVO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
AlvotechNASDAQ: ALVO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $10.29M rose 24.6% year over year, ahead of the +23.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.
Context
- Depreciation & amortization amounted to 6.5% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +24.6% holds above the trailing-twelve-month pace of +23.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 37.85M USD
- Year-over-year change
- +20.9%
- 4-year CAGR
- +20.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.85M | +20.9% |
| FY2024 | 2024-12-31 | 31.3M | +29.3% |
| FY2023 | 2023-12-31 | 24.21M | +18.6% |
| FY2022 | 2022-12-31 | 20.41M | +12.2% |
| FY2021 | 2021-12-31 | 18.2M | — |
Depreciation & Amortization vs competitors
How ALVO compares with its peers on the latest reported figures
- ALVO's LTM Mar 2026 depreciation & amortization of $39.88M is the 9th largest of the 11 companies compared; the peer median is $285.93M.
- Its year-over-year change of +23.2% is the 4th highest of 11, against a peer median of +8.4%.
- Depreciation & amortization amounts to 7.1% of revenue for ALVO, versus a peer median of 6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.67B | -15.5% | +14.8% | 12.2% | |
| LTM Jun 2026 | $989M | -3.3% | -8.5% | 5.7% | |
| LTM Jun 2026 | $842.9M | +13.2% | +14.6% | 8.5% | |
| LTM Jun 2026 | $528.6M | +3.6% | +16.8% | 3.4% | |
| LTM Sep 2026 | $344M | +0.6% | +19.4% | 5.6% | |
| LTM Mar 2026 | $227.86M | +19.7% | +16.7% | 28.6% | |
| LTM Jun 2026 | $194.29M | -20.8% | -2.4% | 6.2% | |
| LTM Mar 2026 | $57.48M | +44.0% | +30.0% | 8.0% | |
| LTM Mar 2026 | $39.88M | +23.2% | +22.9% | 7.1% | |
| LTM Mar 2026 | $20.35M | +25.1% | +75.1% | 7.6% | |
| LTM Mar 2026 | $4.16M | +118.2% | +31.6% | 4.8% | |
| Peer median (excluding ALVO) | $285.93M | +8.4% | +16.7% | 6.9% | |
Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.5M) | (513.58M) | (551.73M) | (231.86M) | 27.92M |
| Depreciation & Amortization | 18.2M | 20.41M | 24.21M | 31.3M | 37.85M |
| Deferred Income Tax | (47.69M) | (38.07M) | (99.32M) | 14.3M | 108.43M |
| Stock-Based Compensation | 0 | 10.32M | 18.03M | 7.63M | 17.38M |
| Change in Working Capital | (6.81M) | (47.89M) | 26.33M | (288.64M) | (117.64M) |
| Accounts Receivables | (13.53M) | (13.23M) | (24.83M) | (164.24M) | (6.33M) |
| Inventory | (29.41M) | (32.41M) | (11.3M) | (49.97M) | (90.13M) |
| Accounts Payables | 14.32M | 0 | 0 | 0 | (21.18M) |
| Other Working Capital | 21.81M | (2.25M) | 62.46M | (74.44M) | 0 |
| Other Non-Cash Items | (90.36M) | 256.42M | 270.29M | 230.44M | (124.14M) |
| Operating Cash Flow | (228.17M) | (312.39M) | (312.19M) | (236.84M) | (50.2M) |
| Capital Expenditures | (40.63M) | (49M) | (46.47M) | (57M) | (64.47M) |
| Acquisitions (Net) | 0 | 0 | 0 | 12M | (14.04M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | (31.66M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 5.95M |
| Other Investing Activities | (20.17M) | (25.66M) | (13.11M) | 22.79M | 0 |
| Investing Cash Flow | (40.63M) | (63.54M) | (46.34M) | (18.87M) | (104.22M) |
| Debt Repayment | 68.98M | 257.82M | 171.2M | 151.98M | 202.48M |
| Common Stock Issued | 185.86M | 9.83M | 136.88M | 150.45M | 78.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 157.27M | (6.76M) | (5.13M) | (10.37M) |
| Financing Cash Flow | 254.83M | 424.91M | 301.32M | 297.31M | 270.83M |
| Effect of Forex Changes | (161K) | (113K) | 1.94M | (1.32M) | 4.51M |
| Net Change in Cash | (14.13M) | 48.87M | (55.27M) | 40.27M | 120.93M |
| Free Cash Flow | (268.8M) | (361.39M) | (358.66M) | (293.84M) | (114.67M) |
Alvotech
NASDAQ:ALVO
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.